In an exploratory biomarker analysis of IMpassion 130, PFS and OS were evaluated based on PD-L1 expression on immune cells and tumor cells, intratumoral CD8, stromal TILs, and BRCA1/2 mutations [24]. Here, CD8A is linked to neoplasm.